Phase III Study: Rituxan Improved PFS By 79% In Advanced Follicular Lymphoma
ASCO Calls On NCI To Double Funding For Cooperative Group Clinical Trials
Tasigna Shows Benefit Over Gleevec In Phase III Study for Ph+ CML In Chronic Phase
Bosutinib Vs. Imatinib Study Didn’t Meet Primary Endpoint
Autologous BMT Equivalent To Allogeneic For Myeloma
Non-Adherence To Protocol Explains Outcome Differences In Hispanic Children With ALL
Afinitor Delayed Progression Compared To Tamoxifen Alone In Randomized Phase II Study
AZURE Trial: Zoledronic Acid Didn’t Improve DFS In Stage II/III
Survival For ALL Increased To 94 Percent In Recent Years
TTF Increased Survival Compared To Chemotherapy
Randomized Trial Finds Sunscreen Use Cuts Risk Of Developing Melanoma
Clinical Trials Approved By NCI CTEP Last Month
Trending Stories
- Montefiore Einstein Director Edward Chu dies of glioblastoma at 66
- Arnold D. Kaluzny, longtime adviser to the NCI and health services researcher, dies at 87
- Christine Lovly to lead City of Hope’s new national thoracic oncology program
- Ellen Sigal and Karen Knudsen “gush” about new CDER Director Richard Pazdur and his late wife, Mary
- FDA to remove black box warnings on hormone therapy for menopause
Trump-era “gold standard science” is not to be confused with gold standard of scientific evidence - Smoldering multiple myeloma: Rethinking the waiting game
